The patent offices of the United States of America and Canada have granted patents for Peakadilly's core technology, COFRADIC�. COFRADIC� allows the identification and quantification of proteins in any biological sample and represents the most important component of the company's MASStermind� biomarker discovery engine.

"We are extremely pleased with the decisions of the US, Canadian and European Patent Offices", says Dr Koen Kas, Chief Executive Officer at Peakadilly. "We are now able to operate on the world's most important pharmaceutical markets offering a proprietary platform for the discovery of protein biomarkers. The patent protection is an important milestone which opens up new opportunities for the marketing of our services and for the out-licensing of our technologies to partner companies."

This protemics technology can analyse huge sets of proteins and posttranslational modified proteins in clinical samples like blood or sputum, and can be useful during clinical trials to distinguish responders from non-responders in a specific therapeutic regimen. A review article discussing how such technologies can help in cancer therapeutics have been published by Dr. Kas in the European Journal of Cancer Prevention (abstract only, full text available to subscribers).